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Abstract
Background: 7B2 is a regulator/activator of the prohormone convertase 2 which is involved in the
processing of numerous neuropeptides, including insulin, glucagon and pro-opiomelanocortin. We have
previously described a suggestive genetic linkage peak with childhood obesity on chr15q12-q14, where the
7B2 encoding gene, SGNE1 is located. The aim of this study is to analyze associations of SGNE1 genetic
variation with obesity and metabolism related quantitative traits.
Methods: We screened SGNE1 for genetic variants in obese children and genotyped 12 frequent single
nucleotide polymorphisms (SNPs). Case control analyses were performed in 1,229 obese (534 children
and 695 adults), 1,535 individuals with type 2 diabetes and 1,363 controls, all French Caucasians. We also
studied 4,922 participants from the D.E.S.I.R prospective population-based cohort.
Results: We did not find any association between SGNE1 SNPs and childhood or adult obesity. However,
the 5' region SNP -1,701A>G associated with higher area under glucose curve after oral glucose tolerance
test (p = 0.0005), higher HOMA-IR (p = 0.005) and lower insulinogenic index (p = 0.0003) in obese
children. Similar trends were found in obese adults. SNP -1,701A>G did not associate with risk of T2D
but tends to associate with incidence of type 2 diabetes (HR = 0.75 95%CI [0.55–1.01]; p = 0.06) in the
prospective cohort.
Conclusion: SGNE1 genetic variation does not contribute to obesity and common forms of T2D but may
worsen glucose intolerance and insulin resistance, especially in the background of severe and early onset
obesity. Further molecular studies are required to understand the molecular bases involved in this process.
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Background
Obesity is a major risk factor for metabolic disorders such
as hypertension, dyslipidemia and type 2 diabetes (T2D)
[1]. The increased prevalence of metabolic diseases is now
affecting young populations as a direct consequence of
the increase in childhood obesity [2]. There is evidence for
a genetic contribution to the obesity epidemic, especially,
for severe forms of obesity, including childhood obesity
and severe adult obesity (BMI ≥ 40 Kg/m2) [3].
We previously performed a family based genome-wide
scan using microsatellite markers and identified a sugges-
tive obesity susceptibility linkage peak on chromosome
15q12-14 [4]. SGNE1  (Secretory Granule NeuroEndo-
crine protein 1) coding for 7B2 peptide is located within
the 95% confidence interval of this linkage peak [4]. 7B2
mRNA and protein are located in either primarily neuro-
nal (e.g hypothalamus) or endocrine (e.g pancreas and
gastrointestinal tract) tissues [5]. 7B2 is a chaperone of the
proprotein convertase (PC) 2 [6]. Pro7B2, the 7B2 peptide
precursor, regulates the processing of proPC2 and is essen-
tial for the activation and regulation of PC2 in secretory
granules of neuroendocrine cells [7].
PC2 is an endoprotease involved in the processing of sev-
eral neuropeptides including proinsulin [8], proglucagon
[9], pro-opiomelanocortin (POMC) [10] and the cocaine
amphetamine regulated transcript (CART) [11]. 7B2 may
also affect regulated hormone secretion [12]. Mice studies
have shown that invalidation of the genes encoding either
PC2 or 7B2 generates major hormone processing defi-
ciency in vivo [13] and is lethal for gene encoding 7B2 in
some genetic backgrounds in mice [14]. Interestingly,
adrenalectomization of 7B2 knockout mice avoided the
lethal phenotype but these animals developed severe
obesity [15].
According to this physiological data and the genetic posi-
tion of SGNE1 under an obesity linkage peak, we hypoth-
esized that SGNE1  is a positional candidate gene for
obesity and metabolic disorders in French Caucasians.
Methods
Subjects
Obese
We genotyped 630 obese children (defined as BMI > 97th
percentile for age and sex according to a French cohort
[16]) selected from 424 nuclear families recruited in Lille
through a national media campaign. Genotypes from 105
unrelated obese children recruited in the Children's hos-
pital in Toulouse were also included and, in total, 735
obese children were studied. We selected 534 unrelated
obese children for case/control studies. We also geno-
typed 1219 obese adults (BMI ≥ 30) recruited in Lille or at
Hôtel-Dieu hospital in Paris. We selected 695 unrelated
severely obese (BMI ≥ 40) and 620 unrelated moderately
obese (30 ≤ BMI < 40) adults for case/control analyses.
The moderate obese adults are sib pairs of severely obese
and parents of obese children.
Type 2 diabetics
We genotyped 360 unrelated type 2 diabetic patients
recruited by the Centre National de la Recherche Scientifique
(CNRS) and Institut Pasteur in Lille and 1175 unrelated
type 2 diabetic patients recruited from Endocrinology-
Diabetology Department in the Corbeil-Essonne Hospi-
tal, Evry.
Controls
Control participants were composed of 623 individuals
recruited by CNRS and Institut Pasteur in Lille or through
the "Fleurbaix-Laventie Ville Santé" study. Additional 740
control subjects were selected among participants of the
Data from the Epidemiology Study on the Insulin Resist-
ance (D.E.S.I.R) study. Control participants were pooled
for case control analyses. χ2 tests did not show significant
difference in genotype and allele frequencies between
both control groups (0.253 ≤ p ≤ 0.886).
Cohort
Participants are from the D.E.S.I.R study, a 9 year follow-
up study. We genotyped 4,922 subjects that had data
available at baseline (M/F ratio: 49.6/50.4%; age = 47.2 ±
10.0 yrs; BMI = 24.7 ± 3.8 kg/m2). Among them, 4,387
subjects were normoglycemic (fasting plasma glucose<6.1
mmol/l) and 3,370 (77%) were followed for incident
impaired fasting glucose (IFG) and T2D. A total of 3,645
participants were non obese (BMI<27 kgm2) at baseline,
and 2,829 (78%) could be followed for overweight and
obesity. After 9 years of follow-up, 2,053 subjects were
both non obese and normoglycemic. T2D was defined as
fasting plasma glucose ≥ 7.0 mmol/l and/or diabetes treat-
ment.
All adult participants and parents of children signed
informed consent. The genetic study was approved by eth-
ical committees at corresponding recruitment centres in
Hôtel-Dieu in Paris, C.H.R.U in Lille, Bicêtre Hospital for
D.E.S.I.R study, Toulouse Children's Hospital.
Measurements
Weight and height were measured by trained personnel
and BMI was calculated as weight/height2 (Kg/m2). Dur-
ing an oral glucose tolerance test (OGTT), participants
received after a 12 h overnight fast 1 g glucose/kg if sub-
ject's weight was <50 kg or 75 g glucose if subject's weight
was ≥ 50 kg. Blood samples were collected after 0, 30, 60,
90 and 120 min for measurement of plasma glucose using
the glucose oxidase procedure and insulin using double-
antibody radioimmunoassays. Glucose and insulinBMC Medical Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2350/8/44
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related traits were only analyzed in subgroups of 590
obese children and 575 obese adults, all normal glucose
tolerant (NGT) (fasting glycemia<6.1 mmol/l). The
insulinogenic index was calculated as (Ins30min-Ins0min/
Glc30min-Glc0min) and HOMA-IR was calculated as Ins0min/
[22.5e-ln(Glc0min)].
Screening for SNPs
SGNE1  has 6 exons and spans 55 kb. We directly
sequenced coding regions including exons, exons/introns
boundaries, 3 kb upstream ATG codon (including non
coding exon1 and intron1) and 1 Kb downstream the stop
codon. We used DNA from 48 unrelated obese children
and 24 unrelated control adults. PCR amplifications were
purified with Montage PCR384 Multiscreen®S384PCR
(Millipore). Sequencing was performed using the auto-
mated ABI Prism 3730xl DNA sequencer in combination
with the Big Dye Terminator cycle (Applied Biosystems)
and purification sequencing reaction with Multi-
Screen®SEQ384 filter plates (Millipore). Data from Hap-
Map phase I was used to select TagSNPs (MAF≥0.05 in
CEU population) to improve the genetic coverage of
SGNE1.
Genotyping
SNPs identified by direct sequencing were genotyped
using either the LightCycler™ or LightTyper™ technologies
(Roche). TagSNPs selected from HAPMAP I, and SNP -
1,071A>G in the cohort were genotyped by the Applied
Biosystems SNPlex™ technology based on the Oligonucle-
otide Ligation Assay (OLA) combined with multiplex PCR
target amplification. Allelic discrimination was performed
through capillary electrophoresis analysis using an
Applied Biosystems 3730xl DNA Analyzer and
GeneMapper3.7 software. All SNPs were re-genotyped in
a subset of 379 individuals by direct sequencing to check
for genotyping discrepancies. Genotyping error rates were
≤ 0.01 for all SNPs. Hardy-Weinberg equilibrium (HWE)
was tested in controls and was verified for all SNPs (0.11
≤ p ≤ 0.68).
Statistical analyses
Tests for deviation from HWE and for association were
performed by the De Finetti program [17]. Case control
analyses for haplotype were performed using THESIAS
software [18]. All possible combinations of 1 to 4 SNPs
were tested. Haplotypes with a frequency of less than 1%
were excluded. Analyses were conducted on inferred and
observed genotypes. OGTT glycaemia and insulinemia
were analysed by General Linear Model ANOVA for
repeated measures. All other quantitative traits (QTs) were
analyzed by a univariate ANOVA General Linear Model
adjusted for sex, age, BMI, using SPSS 14.0 for windows.
Haplotypes associations with QTs were performed using
UNPHASED software [19]. Bonferroni correction was
applied to quantitative traits as significance threshold
(0.05) divided by the number of tests (12 SNPs × 9 QTs =
108) per population. Threshold of significance after
adjustment for multiple testing was 0.0005. Survival
curves were modelled and analysed by the Kaplan-Meier
and Cox tests using R Foundation statistical software (ver-
sion 2.4.0)
Results
We identified four frequent (minor allele frequency ≥ 5%)
and eight rare SNPs by direct sequencing. Frequent SNPs
(-1,839A>T, -1,701A>G, -706C>G -304A>G) were all
located in the 5' region. In order to improve the genetic
coverage of SGNE1, we selected TagSNPs from the Hap-
Map phase I. SNPs with a low genotype call rate (<70%)
were not analyzed. Thus, eight TagSNPs all located in
introns were added and 12 SNPs (Figure 1) were investi-
gated for association with obesity and related phenotypes.
Clinical characteristics of the populations studied are pre-
sented in Table 1. Obesity case control analyses are pre-
sented in the Table 2. None of the SGNE1  SNPs or
SGNE1 genetic variation (A) and LD (B) maps Figure 1
SGNE1 genetic variation (A) and LD (B) maps. 
Genetic variation map: SNPs with MAF ≥ 0.05 are indi-
cated in bold character. SNPs positions were allocated 
according to the human genome variation society nomencla-
ture http://www.hgvs.org/mutnomen/disc.html#SNP. IVS = 
intronic variation sequence. rs numbers were indicated for 
frequent SNPs when available. SNP 1,701A>G is underlined. 
LD map: LD map was generated using Haploview program. 
SNPs positions are on scale. LD (measured by correlation 
coefficient R2) was presented in boxes that correspond to 
the intersection of two SNPs (e.g. LD between 
rs13850_1839 and rs11635997_1071 is of 6%).
-304 A>G
-706C>G
rs12595007
-1,701A>G
rs11635997
-1,839A>T
rs13850
-1,866 C>T
-2,431 C>A
-2,298 C>T
P153P G>A
+437 C>T
+875 A>G
+963G>A
-933 C>T
IVS3 -13,276 T>C
rs1406387
IVS3 -9,221A>G 
rs8037112
IVS3 -3,045 A>C
rs7170561
IVS3 -2,058 A>G
rs28688414
IVS3 +823 A>T
rs12442397
IVS3 +881 A>C
rs12438604
IVS4 +1,514 G>C
rs12592208
IVS4 +2,853 A>T 
rs11638903BMC Medical Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2350/8/44
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haplotype combination (data not shown) studied showed
a significant association with severe forms of obesity in
our populations. Thus, as expected, the contribution of
these SNPs to linkage with childhood obesity observed on
chromosome 15q12-q14 was not significant (data not
shown). We also analyzed association of SGNE1  SNPs
with moderate obesity (30 ≤ BMI ≤ 40). Case control anal-
yses in additional 620 subjects did not show significant
association with this less severe form of obesity (0.06 ≤ p
≤ 0.87; data not shown).
We then investigated associations between SGNE1 SNPs
and obesity related quantitative traits in obese subjects.
SNP-1,701A>G, located in intron 1 which is part of the 5'
region of SGNE1 (Figure 1), showed several strong and
consistent associations with glucose intolerance. In obese
children, despite no significant difference for fasting glu-
cose, SNP -1,701A>G associated with an average 0.5
mmol/l increase (p = 0.0002) in glucose levels 30 min
after an OGTT (Figure 2A) suggesting that -1,701A>G
might alter the early insulin response after a glucose load.
Indeed, the allele -1,701A carriers showed a 27% decrease
in the insulinogenic index, an estimator of insulin secre-
tion capacity (p = 0.0003) (Figure 3). Differences in glu-
cose levels according to -1,701A>G genotypes were still
significant after 120 min (p = 0.005). Thus, -1,701A>G
associated with a 6% increase in the area under the curve
(AUC) for glucose after OGTT (Figure 3; p = 0.0001). On
the other hand, excepting for a borderline association
with fasting insulin levels (p = 0.034), no significant dif-
ferences were observed according to the -1,701A>G geno-
type for insulin levels during the OGTT (Figure 2B).
Consequently, SNP -1,701A>G did not associate with
AUC for insulin (p = 0.141) (Figure 3). However, the -
1,701A allele associated with higher circulating fasting
levels of pro-insulin in obese children (p = 0.037, data not
shown).
In obese NGT adults, SNP -1,701A>G was also associated
with glucose levels but only after 60 min (p = 0.038) and
tended to be associated with higher levels at 90 min (p =
0.06) and 120 min (p = 0.085) (Figure 2C). Accordingly,
we only observed a trend for an association between -
1,701A>G and the AUC for glucose (p = 0.06) in obese
adults (Figure 3). In addition to association with higher
fasting insulin levels (p = 0.028), which was also seen in
children, SNP -1,701A>G was associated with higher insu-
lin levels after 60 min (p = 0.013), 90 min (p = 0.012) and
120 min (p = 0.001) (Figure 2D). Thus, SNP -1,701A>G
associated with a higher AUC for insulin (p = 0.003) (Fig-
ure 3). SNP -1071A>G also associated with a higher insu-
lin resistance index HOMA-IR in obese children (p =
0.005) and adults (p = 0.009) (Figure 3). The associations
with AUC glucose and insulinogenic index continue
reaching significance after Bonferroni correction in obese
children only (for more details, see methods/statistical
analyses). No haplotype combination showed stronger or
independent association from -1,701A>G with glucose
levels, insulinogenic index and HOMA-IR in obese chil-
dren and obese adults (data not shown).
We then investigated the role of SNP -1,701A>G in the
risk of T2D. We genotyped SGNE1  SNPs, including -
1,701A>G in an independent population of 1,535 type 2
diabetics. SGNE1 SNPs or halpotypes (data not shown)
did not associate with T2D (Table 2) in the whole popu-
lation or in groups stratified for obesity or age of T2D
onset before 45 y (data not shown). Logistic regression
using age and sex as covariates did not show any signifi-
cant association between T2D and SNP -1,701A>G either.
Interestingly, SNP -1,701A>G was associated with a
higher BMI in type 2 diabetic patients (mean AA = 33.6 ±
0.4 kg/m2 vs AG/GG = 32.5 ± 0.3 kg/m2; p = 0.022, data
not shown) but not HbA1C levels (mean AA = 8.26 ± 0.1
vs. AG/GG 8.42 ± 0.1; p = 0.29, data not shown).
We then aimed to assess if the SNP -1,701A>G modulates
traits related to obesity and glucose intolerance in a pop-
ulation-based cohort. Thus, SNP-1,701A>G was also gen-
otyped in 4,922 participants from the D.E.S.I.R
prospective study. Cross sectional analyses at baseline did
not show an association of SNP -1,701A>G with fasting
glucose, fasting insulin, HbA1c levels, HOMA-IR or BMI
(data not shown). Only fasting glucose and fasting insulin
Table 1: Clinical characteristics of the populations studied.
Obese Children
N = 735
Obese Adults
N = 1315
T2D
N = 1535
Control 1
N = 623
Control 2
N = 740
Age (years) 11.3 ± 3.2 48 ± 13 59 ± 11 50.9 ± 12 53 ± 5.6
BMI (kg/m2) 28.8 ± 6.2 41.5 ± 8.8 29.3 ± 5.8 22.9 ± 2.3 23 ± 1.8
Sex ratio (F/M) 386/349 874/441 890/645 380/243 444/296
Obesity (%) 100 100 37 0 0
Type 2 Diabetes (%) 12 9 1 0 0 0 0
NGT (%) 94 52 0 100 100
Fasting Glucose (mmol/l) 4.95 ± 0.5 6.66 ± 2.6 9.40 ± 3.3 5.00 ± 0.4 5.05 ± 0.88
Fasting Insulin (pmol/l) 81.0 ± 58 88.2 ± 60 66.0 ± 54 33.5 ± 25 30.5 ± 22BMC Medical Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2350/8/44
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Table 2: Obesity and T2D case control analyses for SGNE1 SNPs. OR: odds ratio. ORs and p values are for allele frequencies 
comparisons. χ2 test and the p values were computed with De Finetti program [17]. All obese cases are the pooled sample of obese 
children and severely obese adults.
Genotype Frequencies Allele Frequencies OR [95%CI] (p value)
-1839 A>T rs13850 AA AT TT A T
Obese Children 384 128 21 0.84 0.16 1.10 [0.90–1.34] (0.335)
Severely obese adults 475 164 20 0.85 0.15 1.06 [0.88–1.28] (0.515)
All obese 859 292 41 0.84 0.16 1.08 [0.92–1.26] (0.327)
Type 2 Diabetes 777 306 20 0.84 0.16 1.08 [0.92–1.26] (0.339)
Controls 950 335 25 0.85 0.15
-1,701 A>G rs11635997 AA AG GG A G
Obese Children 191 267 90 0.59 0.41 1.14 [0.98–1.31] (0.078)
Severely obese adults 266 322 101 0.62 0.38 1.01 [0.88–1.16] (0.837)
All obese 457 589 191 0.61 0.39 1.07 [0.95–1.20] (0.255)
Type 2 Diabetes 554 722 208 0.62 0.38 1.03 [0.92–1.15] (0.619)
Controls 496 618 178 0.62 0.38
-706 C>G rs12595007 CC CG GG C G
Obese Children 384 111 10 0.87 0.13 0.83 [0.67–1.10] (0.081)
Severely obese adults 439 170 10 0.85 0.15 1.01 [0.84–1.21] (0.930)
All obese 823 281 20 0.86 0.14 0.92 [0.79–1.26] (0.343)
Type 2 Diabetes 976 352 21 0.85 0.15 0.95 [0.82–1.10] (0.511)
Controls 970 357 28 0.85 0.15
-304 A>G AA AG GG A G
Obese Children 445 59 5 0.93 0.07 1.13 [0.84–1.51] (0.402)
Severely obese adults 587 91 2 0.93 0.07 1.17 [0.90–1.52] (0.240)
All obese 1032 150 7 0.93 0.07 1.15 [0.92–1.44] (0.210)
Type 2 Diabetes 1187 145 3 0.94 0.06 0.93 [0.74–1.17] (0.555)
Controls 1194 151 6 0.94 0.06
IVS3 -13,276 T>C rs1406387 TT TC CC T C
Obese Children 218 239 93 0.61 0.39 1.00 [0.86–1.15] (0.996)
Severely obese adults 243 340 102 0.60 0.40 1.05 [0.91–1.19] (0.510)
All obese 461 579 195 0.61 0.39 1.02 [0.92–1.14] (0.664)
Type 2 Diabetes 552 729 251 0.60 0.40 1.06 [0.96–1.18] (0.234)
Controls 499 666 191 0.61 0.39
IVS3-9,221 A>G rs8037112 AA AG GG A G
Obese Children 219 233 91 0.62 0.38 0.96 [0.83–1.11] (0.606)
Severely obese adults 260 322 95 0.62 0.38 0.95 [0.82–1.08] (0.422)
All obese 479 555 186 0.62 0.38 0.97 [0.85–1.07] (0.408)
Type 2 Diabetes 525 669 209 0.61 0.39 0.98 [0.88–1.10] (0.774)
Controls 481 666 190 0.61 0.39
IVS3 -3,045 A>C rs7170561 AA AC CC A C
Obese Children 248 211 66 0.67 0.33 1.04 [0.89–1.21] (0.621)
Severely obese adults 318 282 79 0.68 0.32 1.03 [0.89–1.18] (0.541)
All obese 566 493 145 0.67 0.33 1.03 [0.92–1.16] (0.598)
Type 2 Diabetes 627 603 155 0.67 0.33 1.05 [0.94–1.18] (0.372)
Controls 611 586 129 0.68 0.32BMC Medical Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2350/8/44
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IVS3-2,058 A>Grs28688414 AA AG GG A G
Obese Children 307 184 33 0.76 0.24 1.00 [0.85–1.19] (0.959)
Severely obese adults 394 241 44 0.76 0.24 1.02 [0.88–1.19] (0.750)
All obese 701 425 77 0.76 0.24 1.01 [0.89–1.15] (0.809)
Type 2 Diabetes 803 480 94 0.76 0.24 1.03 [0.91–1.16] (0.678)
Controls 778 499 71 0.76 0.24
IVS3 +823 A>T rs12442397 AA AT TT A T
Obese Children 249 215 70 0.67 0.33 1.14 [0.98–1.32] (0.094)
Severely obese adults 320 293 64 0.69 0.31 1.03 [0.89–1.18] (0.670)
All obese 569 508 134 0.68 0.32 1.08 [0.96–0.1.21] (0.217)
Type 2 Diabetes 720 619 166 0.68 0.32 1.05 [0.94–1.18] (0.347)
Controls 642 583 117 0.70 0.30
IVS3 +881 A>C rs12438604 AA AC CC A C
Obese Children 323 184 35 0.77 0.23 1.16 [0.98–1.38] (0.073)
Severely obese adults 416 238 27 0.79 0.21 1.04 [0.89–1.22] (0.630)
All obese 739 422 62 0.78 0.22 1.09 [0.96–1.25] (0.181)
Type 2 Diabetes 903 463 81 0.78 0.22 1.05 [0.92–1.19] (0.459)
Controls 842 450 55 0.79 0.21
IVS4 +2,853 A>T rs11638903 AA AT TT A T
Obese Children 286 199 61 0.71 0.29 0.98 [0.84–1.15] (0.822)
Severely obese adults 335 291 56 0.70 0.30 0.99 [0.86–1.14] (0.885)
All obese 621 490 117 0.71 0.29 0.98 [0.87–1.11] (0.822)
Type 2 Diabetes 703 615 128 0.70 0.30 1.02 [0.91–1.14] (0.772)
Controls 657 588 109 0.70 0.30
IVS4 +1,514 G>C rs12592208 GG GC CC G C
Obese Children 281 195 65 0.70 0.30 0.96 [0.82–1.11] (0.591)
Severely obese adults 313 289 58 0.69 0.31 0.99 [0.85–1.14] (0.873)
All obese 594 484 123 0.70 0.30 0.97 [0.86–1.10] (0.678)
Type 2 Diabetes 716 647 139 0.69 0.31 0.99 [0.89–1.11] (0.911)
Controls 616 579 116 0.69 0.31
Table 2: Obesity and T2D case control analyses for SGNE1 SNPs. OR: odds ratio. ORs and p values are for allele frequencies 
comparisons. χ2 test and the p values were computed with De Finetti program [17]. All obese cases are the pooled sample of obese 
children and severely obese adults. (Continued)
levels were available for the cohort participants. After 9
years follow-up, allele -1,701G carriers tend to be at lower
risk of incidence of overweight (HR = 0.86; p = 0.07),
obesity (HR = 0.84; p = 0.10) and T2D (HR = 0.75; p =
0.06) (Figure 4).
Discussion
Here we describe the genetic study of the pituitary peptide
7B2 encoding gene SGNE1, candidate gene for obesity
and related metabolic traits. Our study does not provide
evidence of association between SGNE1 genetic variation
and severe forms of obesity in large populations of French
Caucasians, including children and adults. However, one
SNP, the -1,701A>G, located in the 5' region of SGNE1,
associate with impaired glucose tolerance in the context of
severe obesity but does not increase the risk for T2D. A
limitation of our study design is that SNP tagging was
based on data from HapMap phase I. According to Hap-
Map phase II data [20] genotypes from 18 additional Tag-
SNPs would be necessary for an extensive genetic coverage
and comprehensive association analyses of SGNE1 with
metabolic diseases.
Our results support that SNP -1,071A>G, although not
associated with obesity, may contribute to higher glucose
levels after OGTT. Similar findings were previously
reported for USF1 (Upstream Stimulatory Factor 1), where
SNPs were associated with higher glucose after OGTT,BMC Medical Genetics 2007, 8:44 http://www.biomedcentral.com/1471-2350/8/44
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although allelic frequencies were similar between T2D
cases and controls [21]. SNP -1,701A>G also associated
with higher HOMA-IR and lower insulinogenic index in
obese children. As far as adults are concerned, -1,701A
allele carriers compensate the decreased insulin secretion
capacity over time but their insulin resistance remained
impaired. A high proportion (~75%) of our obese adults
self-reported overweight since childhood which may
explain a shared genetic background of both populations
as previously reported [22]. However, their metabolic pro-
file is fairly diverse: 94% of obese children are glucose tol-
erant after OGTT, against only 52% of the severely obese
adults. These data may elucidate the observed heterogene-
ity between quantitative traits associations in children and
adults. We also believe that obesity related quantitative
traits results should be interpreted with caution in adults
as these analyses are more meaningful in obese children
[23].
SNP-1,701A>G is located in intron 1 and is part of the 5'
region of SGNE1. It has been shown that intron 1
sequences are essential for transcriptional activity of
SGNE1 in human cell lines [24]. A recent study has also
shown that intron 1 of SGNE1 is hypermethylated and
epigenetically silenced in medulloblastomas [25]. This
data supports an important role of intron 1 of SGNE1 and
a potential functional role of SNP -1,701A>G in the regu-
lation of SGNE1. According to in silico analyses [26], SNP
-1,701A creates a theoretical binding site for TCF/LEF1
(Transcription Factor T-Cell specific/Lymphoid Enhancer
binding Factor1). To our knowledge, TCF/LEF1 role in
metabolism has not been described. We note that TCF/
LEF1 belongs to the Wnt signaling pathway that includes
TCL7L2, which harbours highly associated SNPs with T2D
[27]. Further molecular studies are required to elucidate
how SNP -1,701A>G would affect the expression and
function of SGNE1 and ultimately impaired metabolism.
An increase of 7B2 has been reported in pancreas from ob/
ob mice compared to wild type mice [28] suggesting that
7B2 may increase in insulin resistance state. Thus, as 7B2
is immunologically detected in human plasma [29], anal-
yses of association between SNP -1,701A>G and 7B2
plasma levels in our populations would provide a value
indication about how this genetic variant might impact
SGNE1 functionality and consequently, glucose tolerance
and insulin resistance.
As a protein helper and activator of PC2, 7B2 is involved
in the maturation of a large spectrum of molecules play-
ing central roles in weight and glucose homeostasis [5].
7B2 and PC2 are highly expressed in secretory granules of
pancreatic islets and are involved in processing of insulin
in β-cells and glucagon in α-cell [5]. High levels of circu-
lating pro-insulin and pro-glucagon have been described
in 7B2 knock-out mice confirming the role of 7B2 in insu-
lin and glucagon maturation [30]. If associations and
functionality of SNP -1,701A>G are confirmed, we
hypothesize that higher glucose levels and lower insulin
SNP -1,701A>G associations with insulin and glucose related  traits in obese children and obese adults Figure 3
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related traits in obese children and obese adults. 
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secretion observed in -1,701A allele carriers could be
direct, as a consequence of impairment of the processing
and/or secretion of insulin. The observed SNP -1,701A>G
associations with higher pro-insulin levels and lower
insulinogenic index in obese children support this
hypothesis. Insulin secretion could also be indirectly
affected through alteration of glucagon processing that
requires both PC2 and 7B2. Thus, impairment of gluca-
gon processing may affect insulin secretion and results in
increase glucose levels. This hypothesis is supported by a
recent study where low circulating glucagon levels accom-
panied with low 7B2 mRNA and protein levels (but not
PC2 levels) were reported in pancreas of a mouse strain
highly predisposed to age associated glucose intolerance
[31]. Because of the pleitropic function of 7B2, several
mechanisms would result from the alteration of its regu-
lation. Other metabolic pathways could also be affected,
such as the processing of cholecystokinin (CCK) [32], a
gastrointestine peptide that stimulates insulin secretion
from β-cells in healthy subjects [33] and the maturation of
anorexigenic neuropeptides CART [11] and POMC [10]
involved in the regulation of energy balance.
Conclusion
In summary, we report genetic evidence for the role of
SGNE1 genetic variation in glucose intolerance and insu-
lin resistance in the background of young onset obesity.
Further analyses are required to replicate our findings and
to understand the molecular bases of SGNE1 role in the
genetic susceptibility to the risk of glucose intolerance in
response to glucose load.
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